Nkarta, Inc. (NKTX)
2.765
+0.06
(+2.41%)
USD |
NASDAQ |
Sep 02, 16:00
2.70
-0.06
(-2.35%)
Pre-Market: 08:13
Nkarta Research and Development Expense (TTM) : 89.88M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 89.88M |
| March 31, 2026 | 82.01M |
| December 31, 2025 | 81.24M |
| September 30, 2025 | 79.05M |
| June 30, 2025 | 84.06M |
| March 31, 2025 | 86.48M |
| December 31, 2024 | 87.59M |
| September 30, 2024 | 87.82M |
| June 30, 2024 | 85.13M |
| March 31, 2024 | 88.55M |
| December 31, 2023 | 90.90M |
| September 30, 2023 | 95.95M |
| June 30, 2023 | 98.51M |
| March 31, 2023 | 94.64M |
| Date | Value |
|---|---|
| December 31, 2022 | 88.26M |
| September 30, 2022 | 79.44M |
| June 30, 2022 | 72.76M |
| March 31, 2022 | 67.93M |
| December 31, 2021 | 62.21M |
| September 30, 2021 | 55.90M |
| June 30, 2021 | 49.42M |
| March 31, 2021 | 41.59M |
| December 31, 2020 | 35.47M |
| September 30, 2020 | 31.04M |
| June 30, 2020 | 25.95M |
| March 31, 2020 | 21.51M |
| December 31, 2019 | 16.61M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Ironwood Pharmaceuticals, Inc. | 86.86M |
| Theriva Biologics, Inc. | 5.306M |
| Unicycive Therapeutics, Inc. | 9.609M |
| OnKure Therapeutics, Inc. | 46.54M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |